Table 1 Patient characteristics and prior therapy
Characteristic | N (%) |
|---|---|
Median Age (range) | 65 (57–72) |
Gender | |
Male | 13 (93%) |
Female | 1 (7%) |
Histology | |
Clear cell | 13 (93%) |
Papillary | 1 (7%) |
ECOG | |
0 | 9 (64%) |
1 | 5 (36%) |
IMDC risk group | |
Favorable | 1 (7%) |
Intermediate | 12 (86%) |
Poor | 1 (7%) |
Metastatic sites | |
Lymph nodes | 8 (57%) |
Bone | 8 (57%) |
Lung | 7 (50%) |
Liver | 3 (21%) |
Number or prior therapies | |
1 | 12 (86%) |
2 | 1 (7%) |
3 | 1 (7%) |
Most recent therapy | |
Sunitinib | 8 (57%) |
Axitinib | 3 (21%) |
Pazopanib | 2 (14%) |
HIF-2a inhibitor | 1 (7%) |
Best response to most recent therapya | |
PR | 3 (21%) |
SD | 9 (64%) |
PD | 1 (7%) |
Median duration on most recent therapy (months)a | 18 (3–100) |